Compare Sanofi SA (SNY) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Vipshop Holdings Ltd - ADR — how do they compare? Sanofi SA trades at $40.1 (market cap $96.81B), while Vipshop Holdings Ltd - ADR trades at $12.71 (market cap $6.07B). The key difference: Sanofi SA is far larger — about 15.9× Vipshop Holdings Ltd - ADR's market cap, and Sanofi SA pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Vipshop Holdings Ltd - ADR for 49 Days on average.
| SNY | VIPS | |
|---|---|---|
Market Cap | $96.81B | $6.07B |
Volume | 2,081,815 | 3,134,219 |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $20.29 |
52-Week Low | $39.51 | $12.09 |
Typical Hold Time | 94 Days | 49 Days |
Enterprise Value | $116.20B | $2.90B |
Dividend Yield | 6.02% | 4.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
Vipshop Holdings trades at $12.77, showing modest daily gains of 0.16%. The stock presents compelling value with a P/E of 4.12 and P/S of 0.41, significantly below sector averages. Recent earnings showed mixed results with Q2 2026 missing expectations, but the company maintains strong profitability with 9.82% net margins and 24.44% ROE. Technical indicators show a bullish overall signal despite recent price consolidation near key support levels.
The investment case balances deep valuation discounts against growth challenges. Analyst consensus targets $16.17 (26% upside) with 54% buy ratings, though recent earnings misses and consumer spending concerns warrant caution. Strong cash generation and shareholder returns provide downside protection, making VIPS attractive for value investors despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
